The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
Abstract
CONTEXT: Intravenous immunoglobulin (IVIG) enhances immune homeostasis by modulating expression and function of Fc receptors, interfering with activation of complement and production of cytokines, providing anti-idiotypic antibodies, and affecting the activation and effector functions of T and B cells. These mechanisms may explain the effectiveness of IVIG in autoimmune neuromuscular disorders. OBJECTIVE: To systematically review the current status of the treatment of autoimmune neuromuscular diseases with IVIG, with emphasis on controlled trials. DATA SOURCES: Peer-reviewed publications identified through MEDLINE (1966-2003), EMBASE (1974-2003), and references from bibliographies of pertinent articles. Each autoimmune neuromuscular disease term was searched in combination with the term intravenous immunoglobulin. STUDY SELECTION AND DATA EXTRACTION: Criteria for selection of studies included controlled study design, English language, and clinical pertinence. Data quality was based on venue of publication and relevance to clinical care. DATA SYNTHESIS: Outcomes of controlled trials indicate that IVIG at a total dose of 2 g/kg is effective as first-line therapy in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy and as second-line therapy in stiff-person syndrome, dermatomyositis, myasthenia gravis, and Lambert-Eaton myasthenic syndrome. In other controlled studies, IVIG produced a modest, variable, and transient but not statistically significant benefit in patients with inclusion body myositis and paraproteinemic anti-myelin-associated glycoprotein antibody demyelinating polyneuropathy. Intravenous immunoglobulin is not effective in patients with multiple sclerosis who have established weakness or optic neuritis. In myasthenia gravis, it should be reserved for difficult cases or before thymectomy in lieu of plasma exchange. CONCLUSION: Intravenous immunoglobulin is effective in many autoimmune neurologic diseases, but its spectrum of efficacy, especially as first-line therapy, and the appropriate dose for long-term maintenance therapy are not fully established. Further controlled studies of IVIG, combined with a dose-finding effect, pharmacoeconomics, and quality-of-life assessments, are warranted to improve the evidence base for clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oosterhuis, H. (1997) · Cited by 2,397
Epidemiology and estimated population burden of selected autoimmune diseases in the United States
Jacobson, D. L., Gange, S. J., Rose, N. R., & Graham, N. M. H. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4412 · Cited by 1,667
Delves, P. J., & Roitt, I. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007063430107 · Cited by 1,666
Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin
Kazatchkine, M. D., & Kaveri, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejmra993360 · Cited by 1,209
Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A., & Vincent, A. (2001) · Nature Medicine · doi:10.1038/85520 · Cited by 1,183
van der Meché, F. G. A., Schmitz, P. I. M., & the Dutch Guillain–Barré Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261705 · Cited by 1,143
Dalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., & McCrosky, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292704 · Cited by 1,136
Self-citationPolymyositis and Dermatomyositis
Hohlfeld, R., Hofmann, W. W., & Hanley, D. F. (1994) · Neurocritical Care · doi:10.1007/978-3-642-87602-8_72 · Cited by 1,083
Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor
Samuelsson, A., Towers, T. L., & Ravetch, J. V. (2001) · Science · doi:10.1126/science.291.5503.484 · Cited by 1,053
Polymyositis, Dermatomyositis, and Inclusion Body Myositis
Holton, J., Wedderburn, L. R., & Hanna, M. G. (2013) · UCL Discovery (University College London) · Cited by 764
Cited by
Hughes, R. A., & Cornblath, D. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67665-9 · Cited by 1,676
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
ORANGE, J., HOSSNY, E., WEILER, C., BALLOW, M., BERGER, M., BONILLA, F., BUCKLEY, R., CHINEN, J., ELGAMAL, Y., & MAZER, B. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.015 · Cited by 653
How citation distortions create unfounded authority: analysis of a citation network
Greenberg, S. A. (2009) · BMJ · doi:10.1136/bmj.b2680 · Cited by 499
Immunotherapy for Guillain-Barre syndrome: a systematic review
Hughes, R. A. C., Swan, A. V., Raphael, J.-C., Annane, D., van Koningsveld, R., & van Doorn, P. A. (2007) · Brain · doi:10.1093/brain/awm004 · Cited by 463
Metadata
- Authors
- Dalakas, M. C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-05-19
- Volume
- 291
- Issue
- 19
- Pages
- 2367
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1975756380
- Cited by
- 329
- References
- 56
- FWCI
- 18.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. https://app.cochat.ai/papers/10.1001/jama.291.19.2367
- The paper
- Dalakas, M. C. (2004). Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA. https://doi.org/10.1001/jama.291.19.2367
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.